A Phase 2 interventional study of Topotecan/Docetaxel combination and Docetaxel in Lung Cancer, Non-Small Cell and Non-Small-Cell Lung Cancer, sponsored by GlaxoSmithKline. Completed at 85 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-24.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.
Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 16th largest by enrollment of the 188 interventional ones that give a count, is one of 19 that started in 2003, is one of 125 in phase 2, and was the 27th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Second Xiangya Hospital of Central South University · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
CatalYm GmbH · Sites in United States, Germany, Italy and 4 more countries
Ages 18+
Akeso · Sites in China
Ages 18–75
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 143 · Phase 3 32 · Phase 4 2
First in 1996; this study’s year is marked. 19 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 399 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 50 across the 188 interventional studies. Of the 147 that completed or were terminated, 51 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 198 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline: 1 open now, 7 under way, 3 of them phase 3. Of 42 finished, 23 (55%) have results posted.
Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 10th largest by enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2003, is one of 18 in phase 2, and was the 4th registered.
GlaxoSmithKline’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing docetaxel in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06382129Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | 2026-12 |
| NCT06928389Phase 3AkesoIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer | 2027-05 |
| NCT02889666Shanghai Jiao Tong University School of MedicineA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer | 2026-12 |
| NCT07330050Tianjin Medical University Cancer Institute and HospitalWAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | 2026-12-31 |
| NCT06879717iOncturaA Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | 2027-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 54 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Median Time of Overall Survival
Overall survival was defined as the time from randomization to death and it occurs when all randomized participants had at least one year of follow-up past their date of randomization to treatment.
Time frame: Up to one year from Day -1 (randomization)
Number of Participants With One-year Survival
Number of participants with one-year survival were planned to be reported.
Time frame: Up to one year from Day -1 (randomization)
Median Time to Progression
Time to progression is defined as the time between randomization and the first radiologically or clinically documented evidence of progression.
Time frame: Up to one year from Day -1 (randomization)
Response Rate
Response rate is defined as the percentage of participants in the ITT population attaining an overall best response of complete or partial response.
Time frame: Up to one year from Day -1 (randomization)
Response Duration
Response duration is defined as the time from initial radiologically documented response to the first radiologically or clinically documented sign of progression.
Time frame: Up to one year from Day -1 (randomization)
Time to Response-assessed Every 8 Weeks
Time to response is defined as the time between randomization and the first radiologically documented complete or partial response.
Time frame: Every 8 Weeks post randomization
Assessment of Quality of Life-assessed Every 4 Weeks
The effect of treatment regimens on participants-perceived disease status and well-being was assessed using Lung Cancer Symptom Scale (LCSS) that consists of 9 items addressing the time frame of past day: 6 measuring major symptoms for lung malignancies (loss of appetite, fatigue, cough, dyspnea, hemoptysis and pain) and 3 summation items related to total symptomatic distress, activity status and global quality of life. All items are measured by visual analogue scales (VAS) which uses 100 millimeter (mm) lines to determine the intensity of participant responses. The lowest level of symptom intensity or functional disability on the VAS is on left (none) and highest intensity is on right (as much as could be).
Time frame: Every 4 Weeks post randomization
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or it is considered to be medically significant.
Time frame: Up to 16 months
Number of Participants With Grade 1, 2, 3 or 4 Hematologic Toxicities
Hematology parameters included hemoglobin, hematocrit, red blood cell count, white blood cell count with differential leukocyte and platelet count. Differential to include total neutrophils, bands, lymphocytes, monocytes, eosinophil, and basophils. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 1, 2, 3 or 4 hematologic toxicities have been presented.
Time frame: Up to 16 months
Number of Participants With Grade 3 or 4 Clinical Chemical Toxicities
Standard chemistry evaluation included sodium, potassium, chloride, bicarbonate, calcium, phosphorous, magnesium, blood urea nitrogen (BUN)/urea, uric acid, creatinine, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin, total protein and albumin. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 3 or 4 clinical chemical toxicities have been presented.
Time frame: Up to 16 months
Number of Participants With Clinically Significant Abnormal Vital Signs Data
Vital sign parameters included (blood pressure, and pulse rate after five minutes sitting, body temperature). Blood pressure and pulse rate was measured after sitting for 5 minutes. Only participants with clinically significant abnormal Vital sign data was reported.
Time frame: Up to 16 months
This was a multicenter study conducted at 62 centers: 11 in Canada, 5 in Poland, and 46 in the United States from 14 August 2003 to 30 August 2007. A total of 399 participants with advanced non-small cell lung cancer (NSCLC) were enrolled in the study and randomized to treatment.
| Milestone | IV Topotecan + IV Docetaxel | IV Docetaxel |
|---|---|---|
| Started | 202 | 197 |
| Completed | 154 | 160 |
| Not completed | 48 | 37 |
| Withdrew: Adverse event | 24 | 17 |
| Withdrew: Lost to follow-up | 0 | 4 |
| Withdrew: Protocol violation | 3 | 4 |
| Withdrew: Serious adverse events (sae) | 1 | 0 |
| Withdrew: Sponsor decision | 11 | 7 |
| Withdrew: Withdrawal by subject | 8 | 3 |
| Withdrew: No clinical benefit | 1 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Decline in status | 0 | 1 |
Overall survival was defined as the time from randomization to death and it occurs when all randomized participants had at least one year of follow-up past their date of randomization to treatment.
| Weeks | IV Topotecan + IV Docetaxel | IV Docetaxel |
|---|---|---|
| Median Time of Overall Survival | 30.7 (26.1 to 35.9) | 28.6 (23.6 to 36.4) |
Number of participants with one-year survival were planned to be reported.
No measurements were reported for this outcome.
Time to progression is defined as the time between randomization and the first radiologically or clinically documented evidence of progression.
No measurements were reported for this outcome.
Response rate is defined as the percentage of participants in the ITT population attaining an overall best response of complete or partial response.
No measurements were reported for this outcome.
Response duration is defined as the time from initial radiologically documented response to the first radiologically or clinically documented sign of progression.
No measurements were reported for this outcome.
Time to response is defined as the time between randomization and the first radiologically documented complete or partial response.
No measurements were reported for this outcome.
The effect of treatment regimens on participants-perceived disease status and well-being was assessed using Lung Cancer Symptom Scale (LCSS) that consists of 9 items addressing the time frame of past day: 6 measuring major symptoms for lung malignancies (loss of appetite, fatigue, cough, dyspnea, hemoptysis and pain) and 3 summation items related to total symptomatic distress, activity status and global quality of life. All items are measured by visual analogue scales (VAS) which uses 100 millimeter (mm) lines to determine the intensity of participant responses. The lowest level of symptom intensity or functional disability on the VAS is on left (none) and highest intensity is on right (as much as could be).
No measurements were reported for this outcome.
AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or it is considered to be medically significant.
| Participants | IV Topotecan + IV Docetaxel | IV Docetaxel |
|---|---|---|
| Any AEs | 186 | 172 |
| Any SAEs | 58 | 49 |
Hematology parameters included hemoglobin, hematocrit, red blood cell count, white blood cell count with differential leukocyte and platelet count. Differential to include total neutrophils, bands, lymphocytes, monocytes, eosinophil, and basophils. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 1, 2, 3 or 4 hematologic toxicities have been presented.
| Participants | IV Topotecan + IV Docetaxel | IV Docetaxel |
|---|---|---|
| Hemoglobin, Grade 1 | 76 | 107 |
| Hemoglobin, Grade 2 | 95 | 46 |
| Hemoglobin, Grade 3 | 18 | 11 |
| Neutrophils, Grade 1 | 27 | 14 |
| Neutrophils, Grade 2 | 37 | 7 |
| Neutrophils, Grade 3 | 47 | 7 |
| Neutrophils, Grade 4 | 20 | 11 |
| Platelets, Grade 1 | 75 | 10 |
| Platelets, Grade 2 | 20 | 3 |
| Platelets, Grade 3 | 18 | 0 |
| Platelets, Grade 4 | 1 | 0 |
| White blood cell, Grade 1 | 38 | 28 |
| White blood cell, Grade 2 | 51 | 14 |
| White blood cell, Grade 3 | 50 | 13 |
| White blood cell, Grade 4 | 15 | 2 |
Standard chemistry evaluation included sodium, potassium, chloride, bicarbonate, calcium, phosphorous, magnesium, blood urea nitrogen (BUN)/urea, uric acid, creatinine, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin, total protein and albumin. Recording of any hematology toxicity grade was done using National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 2.0. Higher the grade, more is the toxicity. Data for number of participants with grade 3 or 4 clinical chemical toxicities have been presented.
| Participants | IV Topotecan + IV Docetaxel | IV Docetaxel |
|---|---|---|
| Albumin, Grade 3 | 3 | 3 |
| BUN/Urea, Grade 3 | 4 | 2 |
| Creatinine, Grade 3 | 0 | 1 |
| Alkaline Phosphatase, Grade 3 | 1 | 1 |
| AST, Grade 3 | 0 | 1 |
| AST, Grade 4 | 1 | 0 |
| ALT, Grade 3 | 1 | 0 |
| ALT, Grade 4 | 1 | 0 |
| Bilirubin, Grade 3 | 1 | 2 |
| Sodium, Grade 3 | 12 | 9 |
| Sodium, Grade 4 | 0 | 1 |
| Calcium, Grade 3 | 2 | 2 |
| Calcium, Grade 4 | 0 | 1 |
| Potassium, Grade 3 | 7 | 3 |
| Potassium, Grade 4 | 1 | 1 |
| Magnesium, Grade 3 | 4 | 2 |
Vital sign parameters included (blood pressure, and pulse rate after five minutes sitting, body temperature). Blood pressure and pulse rate was measured after sitting for 5 minutes. Only participants with clinically significant abnormal Vital sign data was reported.
| Participants | IV Topotecan + IV Docetaxel | IV Docetaxel |
|---|---|---|
| Number of Participants With Clinically Significant Abnormal Vital Signs Data | 0 | 0 |
Collected over Up to 16 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV Topotecan + IV Docetaxel | 170/200 (85%) | 58/200 (29%) | 181/200 (90.5%) |
| IV Docetaxel | 165/195 (84.6%) | 49/195 (25.1%) | 166/195 (85.1%) |
| Event | IV Topotecan + IV Docetaxel | IV Docetaxel |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 6/200 | 7/195 |
| PneumoniaInfections and infestations | 7/200 | 4/195 |
| AnaemiaBlood and lymphatic system disorders | 6/200 | 0/195 |
| DehydrationMetabolism and nutrition disorders | 6/200 | 2/195 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/200 | 1/195 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/200 | 4/195 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 3/200 | 1/195 |
| DiarrhoeaGastrointestinal disorders | 3/200 | 2/195 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/200 | 0/195 |
| NauseaGastrointestinal disorders | 1/200 | 2/195 |
| Event | IV Topotecan + IV Docetaxel | IV Docetaxel |
|---|---|---|
| FatigueGeneral disorders | 90/200 | 74/195 |
| NauseaGastrointestinal disorders | 57/200 | 43/195 |
| DiarrhoeaGastrointestinal disorders | 51/200 | 40/195 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 46/200 | 36/195 |
| AnaemiaBlood and lymphatic system disorders | 44/200 | 21/195 |
| ConstipationGastrointestinal disorders | 39/200 | 38/195 |
| AnorexiaMetabolism and nutrition disorders | 33/200 | 37/195 |
| AlopeciaSkin and subcutaneous tissue disorders | 36/200 | 35/195 |
| NeutropeniaBlood and lymphatic system disorders | 34/200 | 9/195 |
| Oedema peripheralGeneral disorders | 28/200 | 31/195 |
| Age, Customized(Participants) | IV Topotecan + IV Docetaxel | IV Docetaxel | Total |
|---|---|---|---|
| 18-40 | 4 | 1 | 5 |
| 41-64 | 129 | 116 | 245 |
| >=65 | 69 | 80 | 149 |
| Sex: Female, Male(Participants) | IV Topotecan + IV Docetaxel | IV Docetaxel | Total |
|---|---|---|---|
| Female | 63 | 78 | 141 |
| Male | 139 | 119 | 258 |
| Race (NIH/OMB)(Participants) | IV Topotecan + IV Docetaxel | IV Docetaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 10 | 13 | 23 |
| White | 184 | 183 | 367 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 0 | 3 |
Ran from Aug 2003 to primary completion in Aug 2007, 48 months.
Results were first posted in Jun 2019, 11 years 9 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 48 months is above that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Topotecan · Docetaxel
Carcinoma, Non-Small-Cell Lung →